Accelerated decline in Helicobacter pylori seroprevalence rate during the screen and treat project in Vammala, Finland, as demonstrated in 29- To 45-year-old pregnant women

APMIS

Volumn 112, Issue 1, 2004, Pages 34-38

  Rehnberg Laiho, Leena ^a   Salomaa, Anniina ^a,b   Rautelin, Hilpi ^a,c   Koskela, Pentti ^d   Sarna, Seppo ^c   Kosunen, Timo U ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Vammala Health Centre   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Antibodies; Helicobacter pylori; Population; Seroprevalence

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY;

ADULT; ARTICLE; CHI SQUARE TEST; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ETHNIC GROUP; FEMALE; FINLAND; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MATERNITY WARD; OUTCOMES RESEARCH; POPULATION RESEARCH; PREGNANCY; PRIORITY JOURNAL; SAMPLE; SCREENING; SEROPREVALENCE; STATISTICAL SIGNIFICANCE;

ADULT; AGE FACTORS; ANTIBODIES, BACTERIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FINLAND; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MIDDLE AGED; PILOT PROJECTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SEROEPIDEMIOLOGIC STUDIES; STOMACH DISEASES; URBAN POPULATION;

EID: 1542269336     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2004.apm1120106.x     Document Type: Article

References (23)

1. Parsonnet J. Helicobacter pylori: the size of the problem. Gut 1998;43(Suppl 1):6-9.
2. Parsonnet J. Factors associated with disappearance of Helicobacter pylori in the West. In Hunt RH, Tytgat GNJ, eds. Helicobacter pylori. Basic Mechanisms to Clinical Cure 2000. London, Kluwer Academic Publishers, 2000:45-51.
3. Kosunen TU, Aromaa A, Knekt P, Salomaa A, Rautelin H, Lohi P, et al. Helicobacter antibodies in 1973 and 1994 in the adult population of Vammala, Finland. Epidemiol Infect 1997;119:29-34.
4. Rauws EAJ, Tytgat GNJ. Helicobacter pylori in duodenal and gastric ulcer disease. Baill Clin Gastroenterol 1995;9:529-47.
5. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347-53.
6. Banerjee S, Michetti P. A Helicobacter pylori vaccine is essential. In Hunt RH, Tytgat GNJ, eds. Helicobacter pylori. Basic Mechanisms to Clinical Cure 2000. London, Kluwer Academic Publishers, 2000:643-51.
7. Forman D. Helicobacter pylori and gastric cancer: the risk is real. Helicobacter pylori. Basic Mechanisms to Clinical Cure 2000. London, Kluwer Academic Publishers, 2000:507-11.
8. Bazzoli F, Palli D, Zagari RM, Festi D, Pozzato P, Nicolini G, et al. The Loiano-Monghidoro population-based study of Helicobacter pylori infection: prevalence by 13C-urea breath test and associated factors. Aliment Pharmacol Ther 2001;15:1001-7.
9. Moayyedi P, Feltbower R, Brown J, Mason S, Mason J, Nathan J, et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Lancet 2000;355:1665-9.
10. Salomaa A, Kosunen TU, Aromaa A, Klaukka T, Rautelin H, Rehnberg-Laiho L, et al. "Screen and treat Helicobacter pylori gastritis" project in a western community. Gut 1998;43(Suppl 2):A112.
11. Rothenbacher D, Bode G, Berg G, Knayer U, Gonser T, Adler G, et al. Helicobacter pylori among preschool children and their parents: evidence of parent-child transmission. J Infect Dis 1999;179:398-402.
12. Kosunen TU, Seppälä K, Sarna S, Sipponen P. Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. Lancet 1992;339:893-5.
13. Rehnberg-Laiho L, Rautelin H, Koskela P, Sarna S, Pukkala E, Aromaa A, et al. Decreasing prevalence of helicobacter antibodies in Finland, with reference to the decreasing incidence of gastric cancer. Epidemiol Infect 2001;126:37-42.
14. Mégraud F, Brassens-Rabbe MP, Denis F, Belbouri A, Hoa DQ. Seroepidemiology of Campylobacter pylori infection in various populations. J Clin Microbiol 1989;27:1870-3.
15. Graham DY, Malaty HM, Evans DG, Evans DJ, Klein PD, Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race and socioeconomic status. Gastroenterology 1991;100:1495-501.
16. Goh KL. Update on indications for treatment of Helicobacter pylori (including Maastricht 2). Curr Opin Gastroenterol 2001;17(Suppl 1):S43-6.
17. Blok P, Craanen ME, Offerhaus GJA, Tytgat GNJ. Gastric carcinoma: clinical, pathogenic and molecular aspects. QJM 1997;90:735-49.
18. Graham DY. Can therapy ever be denied for Helicobacter pylori infection? Gastroenterology 1997;113:S113-7.
19. Salomaa A, Martikainen J, Klaukka T, Kosunen TU. Number of antimicrobial treatments for Helicobacter pylori infection in Finland in 1996-1999. Gut 2001;49(Suppl 11):A86.
20. Leivo T. Economic evaluation of selected Finnish screening programmes. Helsinki: Helsinki University, 2001, MD Thesis:27-61.
21. Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996;348:150-4.
22. Fendrick AM, Chernew ME, Hirth RA, Bloom BS, Bandekar RR, Scheiman JM. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Int Med 1999;159:142-8.
23. Mason J, Axon ATR, Forman D, Duffett S, Drummond M, Crocombes W, et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther 2002;16:559-68.